Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.

Oralead Pharma announced that it has received tens of millions of yuan in round of funding on January 29, 2024. The transaction included participation from new investors HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd., and BrightGene Bio-Medical Technology Co., Ltd.